Israeli cancer breakthrough ‘doubles life expectancy’

New drug developed to treat specific type of pancreatic cancer in people who carry BRCA mutation, which is more prevalent among Ashkenasi Jews than the general population.

Cancer cells divide relentlessly, forming solid tumours or flooding the blood with abnormal cells


Israeli scientists have developed a targeted pancreatic cancer therapy for people who carry the BRCA genetic mutation.

The breakthrough will be of interest to Jewish communities around the world, because about one-in-40 people with Ashkenazi Jewish heritage have a mutation of the BRCA1 or BRCA2 gene, compared to one-in-800 of the general population.

Read More…